Over 80 percent of 200 COVID-19 clients in a healthcare facility in Spain have vitamin D shortage, according to a brand-new research study released in the Endocrine Society’s Journal of Clinical Endocrinology & Metabolism.
Vitamin D is a hormonal agent the kidneys produce that controls blood calcium concentration and effects the body immune system. Vitamin D shortage has actually been connected to a range of health issues, although research study is still in progress into why the hormonal agent effects other systems of the body. Many research studies indicate the advantageous result of vitamin D on the body immune system, specifically concerning security versus infections.
“One approach is to identify and treat vitamin D deficiency, especially in high-risk individuals such as the elderly, patients with comorbidities, and nursing home residents, who are the main target population for the COVID-19,” stated research study co-author José L. Hernández, Ph.D., of the University of Cantabria in Santander, Spain. “Vitamin D treatment should be recommended in COVID-19 patients with low levels of vitamin D circulating in the blood since this approach might have beneficial effects in both the musculoskeletal and the immune system.”
The scientists discovered 80 percent of 216 COVID-19 clients at the Hospital Universitario Marqués de Valdecilla had vitamin D shortage, and males had lower vitamin D levels than females. COVID-19 clients with lower vitamin D levels likewise had actually raised serum levels of inflammatory markers such as ferritin and D-dimer.
Reference “Vitamin D Status in Hospitalized Patients With SARS-Cov-2 Infection” 27 October 2020, Journal of Clinical Endocrinology & Metabolism.
Other authors of the research study consist of: Daniel Nan, José M. Olmos, Javier Crespo, and Víctor M. Martínez-Taboada of the University of Cantabria; Marta Fernandez-Ayala, Mayte García-Unzueta, Miguel A. Hernández-Hernández, Marcos López-Hoyos, Manuel Gutiérrez-Cuadra, and Juan J. Ruiz-Cubillán of the Hospital Marqués de Valdecilla-IDIVAL in Santander, Spain; Pedro Muñoz Cacho of the Servicio Cántabro de Salud in Santander, Spain;
The manuscript got financing from Instituto de Salud Carlos III.
